Navigation Links
ChromaDex Partners With Kappa Bioscience to Provide Quality Control Methods, Tools and Services for Vitamin K2
Date:12/2/2010

IRVINE, Calif., Dec. 2, 2010 /PRNewswire-FirstCall/ -- ChromaDex Corporation (OTC Bulletin Board: CDXC), a leader in phytochemical reference standards and related contract analysis and research services, today announced that it has entered into a global agreement with Kappa Bioscience AS (Oslo, Norway) to supply analytical reference standards, quality control methods and related analytical testing services for Vitamin K2, Menaquinone-7(MK-7) in raw materials and finished goods.

"With increasing market demand for Vitamin K2 MK-7, there will be an increase in demand for reference standards, quality control methods, research tools and analytical services," said Frank Jaksch, CEO and co-founder of ChromaDex. "Since MK-7 is a vitamin product manufactured from different sources, it is critical that testing procedures are in place to ensure the quality and consistency of any MK-7 related ingredient or product."

Vitamin K2 is shown to have significant importance for optimal utilization of calcium in the body related to bone and cardiovascular health. Studies indicate that the Western diet is deficient in Vitamin K2. Thus, daily supplementation is expected to be beneficial for the bone building process as well as for cardiovascular health.

"The market needs a reliable and impartial third party expert like ChromaDex to bring clarity to Vitamin K analysis," said Egil Greve, CEO of Kappa Bioscience. "To date it has been difficult, if not impossible, to verify the label claims of Vitamin K2 in nutritional products. We expect that industry interest and confidence in Vitamin K2 will grow now that we can all confirm fortification," he added.  

About ChromaDexChromaDex is a leader in the development of phytochemical and botanical reference standards and the creation of associated intellectual property. ChromaDex is committed to sustainable "green chemistry" and provides the dietary supplement, food, beverage, nutraceutical and cosmetic industries with the novel ingredients, analytical tools and services to meet product regulatory, quality, efficacy and safety standards. The company has worldwide exclusive patent rights related to pterostilbene. For more information, visit http://www.chromadex.com/ or follow ChromaDex on Twitter @ChromaDex.

About Kappa BioscienceKappa Bioscience is the innovative leader and first mover with high purity vitamin K2 as menaquinone-7 (MK-7). Kappa Bioscience is a Norwegian based entity with substantial resources and knowledge about vitamins and vitamin K2 in particular. Kappa Bioscience is currently the only vendor with vitamin K2 as pure MK-7 in various formulations, following a traditional vitamin production process with proprietary and innovative new steps. The company is operating in the US through Xsto Solutions and has its manufacturing in NJ, USA. For further information, visit http://www.kappabio.comCHROMADEX CONTACTSInvestor InquiriesLiviakis Financial Communications, Inc.John M. Liviakis, President415-389-4670John@Liviakis.comChromaDex Contact Jenny RoblesAdministrative Assistant to the CEO10005 Muirlands Blvd, Suite G, Irvine, CA 92618949-419-0288jennyr@chromadex.comMedia ContactMegan LavineCanale Communications3033 5th Ave., Suite 400, San Diego, CA 92103619-849-5388megan@canalecomm.comKAPPA BIOSCIENCE CONTACTSEgil GreveChief Executive Officer+47 95 10 9565egil.greve@kappabio.comArne Johan GrimsboVP Strategy & Bus. Dev+47 90 984824arne.grimsbo@kappabio.com
'/>"/>

SOURCE ChromaDex Corporation
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
2. Multiple Myeloma Research Consortium (MMRC) Partners with Novartis to Advance Phase II Study of Deacetylase Inhibitor
3. Harvard Medical School-Partners HealthCare Center for Genetics and Genomics Successfully Completes Evaluation of AutoGenomics 2C9-VKORC1 Panel to Assess Warfarin Sensitivity
4. HistoRx and Radiation Therapy Oncology Group Initiate Brain Tumor Biomarker Research Partnership
5. The Leukemia & Lymphoma Society and Cleveland Clinic Taussig Cancer Institute Announce Groundbreaking Partnership to Accelerate Drug Approvals
6. PDHI Launches ConXus Rewards, Announces Partnership With Hallmark Insights to Support Incentive-Driven Wellness Programs
7. UNICEF Partners With Causes on Facebook to Launch Charity Gift Feature
8. HealthMedias Strongest Single Quarter Results: Growth Driven by Product Enhancements, New Partnerships
9. iCAD Announces Partnership for Initiating Clinical Testing of Its Virtual Colonoscopy CAD Product
10. Catalyst Pharmaceutical Partners Begins Enrollment for Its U.S. Phase II Clinical Trial of CPP-109 in Patients with Cocaine Addiction
11. UM Maryland Industrial Partnerships Program Approves 18 Collaborative Research Projects, Worth $4.4 Million, Between University Faculty, State Technology Companies
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/11/2017)...  True Health, a leader in integrated diagnostics ... National Breast Cancer Awareness month to educate doctors ... Research recently published in ... than 10 million American women are at significant ... BRCA2 and have not had testing. These mutations can ...
(Date:10/7/2017)... , Oct. 6, 2017   Provista, a ... than $100 billion in purchasing power, today announced a ... information. The Newsroom is the online home ... trends, infographics, expert bios, news releases, slideshows and events. ... to a wealth of resources at their fingertips, viewers ...
(Date:10/4/2017)... Oct. 4, 2017 OBP Medical ... illuminating medical devices, today announced regulatory approval from ... Agency (or Agência Nacional de Vigilância Sanitária (ANVISA)) ... cordless surgical retractor with integrated LED light source ... illumination and exposure of a tissue pocket or ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... The American Board of Family Medicine's (ABFM) Board ... Chief Executive Officer, succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will ... Dr. Puffer’s retirement at the end of 2018. Upon assuming the role of President ...
(Date:10/13/2017)... Nevada (PRWEB) , ... October 13, 2017 , ... ... Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD oil ... required and providing a CBD form that can be easily incorporated into liquid products, ...
(Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder ... of ElderCounsel, a national organization of elder law and special needs planning attorneys. “Membership ... rules. It also provides a forum to network with elder law attorneys nationwide,” said ...
(Date:10/13/2017)... LUIS OBISPO, Calif. (PRWEB) , ... October 13, 2017 , ... ... Alzheimer’s or dementia. However, many long-term care insurance companies have a waiver for care ... is the 90-day elimination period, when the family pays for care, is often waived, ...
(Date:10/13/2017)... New York, NY (PRWEB) , ... October 13, 2017 , ... ... most influential people in business to advocate for action towards gender equality at their ... 18,000 views from around the globe, and reached a social audience of over 3 ...
Breaking Medicine News(10 mins):